Melanoma symptoms provide key warning signs that can help you find this disease early, when it is most treatable. Learn ...

Currently there are no clinically recognized molecular biomarkers for malignant melanoma (MM) for either diagnosing disease stage or measuring response to therapy. The aim of this feasibility study ...

According to the statistics, melanoma accounts for just 11 % of all types of skin cancer, it is responsible for most of the deaths. Melanoma is visually difficult for clinicians to differentiate from ...

Institut Curie researchers have identified a sex-specific molecular pathway connecting E-cadherin loss, estrogen receptor-α ...

Subungual melanoma (SM) is a rare entity; its incidence ranges from 0.7%-3.5% of cutaneous melanomas. [1, 2] It has a poor prognosis due to the delay in the diagnosis.

The abundance in Black skin of melanin, the pigment that gives skin its color, offers extra protection from damaging ...

Overall, the 10-year recurrence rate was 0.8%. The authors conclude that 9-mm margins, rather than the traditional 5-mm margins, are appropriate for melanoma in situ excision.

In this design, mesoporous silica nanoparticles (MSNs) with CuS bundled in the channel are obtained in aqueous solution via in situ growth route for the first time. Furthermore, to achieve a more ...

Stage 0 (melanoma in situ) Melanoma in situ is a term used to describe the earliest stage of melanoma. The melanoma is only in the top layer of skin, called the epidermis. It has not started to spread ...

Specifically, researchers found patients with metastatic melanoma who did not respond to immune checkpoint inhibitors had DNA with differences not found in the DNA of those who did respond.

She was diagnosed with inoperable stage 3 melanoma in 2018 after noticing swelling and lack of strength in her right arm and was initially told she would have immunotherapy infusions for two years.